tirzepatide approved by fda 🚨 Generic Versions of Mounjaro & Zepbound Move Closer as Reviews First Applications The US Food and Drug Administration (FDA) is reviewing the first applications for generic versions of Eli Lilly's FDA approval for Zepbound (tirzepatide)

The Phase 2 data (14.8% weight loss at 13 weeks with reported muscle preservation) are remarkable if confirmed, suggesting rapid, substantial weight loss that approaches semaglutide's 68-week results in just a fraction of the time

Semaglutide enters appetite

Customisation: OEM labelling, documentation and packing options are available for established buyers

Reynaert NL, van der Vliet A, Guala AS, McGovern T, Hristova M, Pantano C, Heintz NH, Heim J, Ho YS, Matthews DE, Wouters EF, Janssen-Heininger YM (2006) Dynamic redox control of NF-kappaB through glutaredoxin-regulated S-glutathionylation of inhibitory kappaB kinase beta

Diabetologia , 57 (4), 781784

The payer will understand Lady T #6 This is from the 2026 Q1 AHA coding clinic #8 The coding clinic referenced above is confusing as both semaglutide and tirzepatide are listed by name in Appendix A: Z codes for long-term use of drugs in the 2026 ICD-10 code book and code to Z79.85